Share on Facebook
Share on Twitter
Share on LinkedIn
Share by Email
Print
Actavis announced the launch of Budesonide Inhalation Suspension, the generic version of AstraZeneca’s Pulmicort Respules.
Pulmicort Respules are indicated as maintenance treatment to control and prevent asthma symptoms in patients aged 12 months to 8 years. Budesonide is an anti-inflammatory corticosteroid that exhibits potent glucocorticoid activity and weak mineralocorticoid activity. Corticosteroids have been shown to have a wide range of inhibitory activities against multiple cell types (eg, mast cells, eosinophils, neutrophils, macrophages, lymphyocytes), and mediators (eg, histamine, eicosanoids, leukotrienes, and cytokines) involved in allergic- and non-allergic-mediated inflammation.
RELATED: New Inhalers for Asthma, COPD Launched
Budesonide Inhalation Suspension is available in 0.25mg and 0.5mg vials.
,p>For more information call (800) 432-8534 or visit Actavis.com.
